Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers
NCT ID: NCT00957398
Last Updated: 2012-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
10 participants
OBSERVATIONAL
2009-08-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
IBS is currently classified into following subtypes:
* Diarrhoea-IBS (IBS-D)
* Constipation-IBS (IBS-C)
* Mixed-IBS (IBS-M)
* Unsubtyped-IBS (IBS-U)
according to the Bristol scale.
Magnetic Tracking System (MTS) is a new minimal invasive technic that allows motility studies of the whole human gastrointestinal tract.
The magnetic cylindrical pill (6x15mm) is swallowed at 9 AM on day one. The recording is made until 4 PM and again from 8 AM until 2 PM on day two. The patient is placed in a bed and will be supplied with standardized food and fluid.
The Magnetic Tracking System consists of a 4 x 4 matrix of sensors positioned with respect to the anatomical reference points. Before measurements, the matrix is calibrated by offsetting the earth's and environmental magnetic fields. During the experiment, the magnet coordinates are continuously monitored and transmitted to a computer for processing and storage. Respiratory artifacts will be filtered out. Digestive movements will then be classified as 1) non-propulsive or 2) propulsive and transformed into either trajectory or dynamic graphs of the digestive motility.
The Magnetic Tracking System has the advantage from both radiographic and scintigraphic methods of conducting the tests without any radiation exposure to the patient. Preliminary studies have shown good concordance between the transit measured with the magnet and radiographic transit times.
The investigators wish to use this method, MTS, to compare the motility of the small intestine and the colon in patients with IBS-D and IBS-C as well as to compare these to groups to MTS done on healthy volunteers under the same conditions as the IBS patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Small and Large Bowel Transit Tests Using MRI (Study 1)
NCT01534507
Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome
NCT01457378
"Functional Bowel Disorder. Investigation in General Practice"
NCT01153295
Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
NCT01787253
Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome
NCT00659763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IBS-D
12 IBS-D patients who will all undergo MTS.
No interventions assigned to this group
IBS-C
12 IBS-C patients who will all undergo MTS.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are diagnosed with IBS according to the Rome III criteria.
* A total symptom score in GSRS-IBS at a minimum of 40 points.
* Patients who are psychologically stable and suitable for observation and able to provide informed consent.
Exclusion Criteria
* Pregnant or breast feeding.
* Patients who are considered unable to follow the planned programme of the study, including mental illness or physiological instability.
* Patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological disease.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Janne Ladefoged Fassov
PhD student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janne Fassov, PhDstudent
Role: PRINCIPAL_INVESTIGATOR
Analfysiologisk Klinik, University Hospital of Aarhus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Analfysiologisk Klinik, University of Aarhus
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20090009,JLF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.